retatrutide trails Retatrutide: Life Changing Results In Phase 3 Trials Proven Retatrutide produces up to 30.3%
Description
Cagrilintide is a long-acting amylin analogue, whilst retatrutide is a novel triple receptor agonist targeting GLP-1, GIP, and glucagon pathways
It means your blood sugar (glucose) levels are elevated but not enough to be Type 2 diabetes
New Research at ACR Convergence 2025 Highlights Potential of GLP-1 Therapies in Rheumatic Disease Management
That is roughly half the time to reach comparable or better results
If the 4 mg arm of the TRIUMPH program confirms maintenance efficacy, titration schedules already covered in our retatrutide dosage guide will need an explicit maintenance-phase section beyond the existing 4-12 mg range
